Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 October 2021Website:
http://www.cogrx.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 9 min agoDividend
Analysts recommendations
Institutional Ownership
CGTX Latest News
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024.
PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open.
Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer John Doyle - Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head, R&D Conference Call Participants Charles Duncan - Cantor Jay Olson - Oppenheimer Aydin Huseynov - Ladenburg Operator Good morning, ladies and gentlemen and welcome to Cognition Therapeutics Second Quarter 2023 Earnings Conference Call. My name is Jenny and I will be your conference operator today.
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative disorders by regulating cellular damage response pathways, announced that it will host a conference call and webcast on June 28, 2023, at 8:00am ET to discuss topline results from its Phase 2 SEQUEL Study (NCT04735536) for mild-to-moderate Alzheimer's disease. During the event, members of Cognition's leadership team and a principal investigator from the trial will review the results.
Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q4 2022 Earnings Conference Call March 23, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Andrew Einhorn - Interim Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Operator Good morning, ladies and gentlemen, and welcome to Cognition Therapeutics Incorporated Fourth Quarter and Fiscal Year 2022 Earnings Conference Call.
What type of business is Cognition Therapeutics?
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
What sector is Cognition Therapeutics in?
Cognition Therapeutics is in the Healthcare sector
What industry is Cognition Therapeutics in?
Cognition Therapeutics is in the Biotechnology industry
What country is Cognition Therapeutics from?
Cognition Therapeutics is headquartered in United States
When did Cognition Therapeutics go public?
Cognition Therapeutics initial public offering (IPO) was on 08 October 2021
What is Cognition Therapeutics website?
https://www.cogrx.com
Is Cognition Therapeutics in the S&P 500?
No, Cognition Therapeutics is not included in the S&P 500 index
Is Cognition Therapeutics in the NASDAQ 100?
No, Cognition Therapeutics is not included in the NASDAQ 100 index
Is Cognition Therapeutics in the Dow Jones?
No, Cognition Therapeutics is not included in the Dow Jones index
When does Cognition Therapeutics report earnings?
The next expected earnings date for Cognition Therapeutics is 08 August 2024